Sepsis is the most common cause of death in medical intensive care units (ICU). If sepsis progresses to refractory septic shock, mortality may reach 90–100% despite optimum current therapy. Extracorporeal cytokine adsorption in addition to regular therapy was studied prospectively in refractory septic shock patients on a medical ICU. Refractory shock was defined as increasing vasopressor dose required to maintain mean arterial blood pressure above 65 mmHg or increasing lactate levels despite protocol-guided shock therapy for 6 h. We analysed noradrenaline requirements after 6 and 12 h (primary endpoint), lactate clearance after 6 and 12 h, SOFA-scores in the first days and achievement of shock reversal (i.e., normalization of lactate concentrations and sustained discontinuation of vasopressors; secondary endpoints). Twenty consecutive patients with refractory septic shock were included; CytoSorb® treatment was started after 7.8 ± 3.7 h of shock therapy. Following the initiation of adsorption therapy, noradrenaline dose could be significantly reduced after 6 (−0.4 µg/kg/min; p = 0.03) and 12 h (−0.6 µg/kg/min; p = 0.001). Lactate clearance improved significantly. SOFA-scores on day 0, 1 and 2 remained unchanged. Shock reversal was achieved in 13 (65%) patients; 28-day survival was 45%. In severe septic shock unresponsive to standard treatment, haemodynamic stabilization was achieved using cytokine adsorption therapy, resulting in shock reversal in two-thirds of these patients. The study was registered in the German Register for Clinical Trials (DRKS) No. 00005149.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33:606–18.
Kumar G, Kumar N, Taneja A, Kaleekal T, Tarima S, McGinley E, et al. Nationwide trends of severe sepsis in the 21st century (2000–2007). Chest. 2011;140:1223–31.
Parrillo JE. Management of septic shock: present and future. Ann Intern Med. 1991;115:491–3.
Levy MM, Macias WL, Vincent JL, Russell JA, Silva E, Trzaskoma B, et al. Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med. 2005;33:2194–201.
Conrad M, Perez P, Thivilier C, Levy B. Early prediction of norepinephrine dependency and refractory septic shock with a multimodal approach of vascular failure. J Crit Care. 2015;30:739–43.
Benchekroune S, Karpati PC, Berton C, Nathan C, Mateo J, Chaara M, et al. Diastolic arterial blood pressure: a reliable early predictor of survival in human septic shock. J Trauma. 2008;64:1188–95.
Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993;328:1471–7.
Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine. 2005;29:169–75.
Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167:1655–63.
Rimmele T, Kellum JA. Clinical review: blood purification for sepsis. Crit Care. 2011;15:205.
Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003;27:792–801.
Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M. Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med. 2008;36:268–72.
Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med. 2008;36:1573–7.
Song M, Winchester J, Albright RL, Capponi VJ, Choquette MD, Kellum JA. Cytokine removal with a novel adsorbent polymer. Blood Purif. 2004;22:428–34.
Schädler D, Porzelius C, Jörres A, Marx G, Meier-Hellmann A, Putensen C, Quintel M, Spies C, Engel C, Weiler N, Kuhlmann M. A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients. eposter Crit Care; 2013.
Peng ZY, Wang HZ, Carter MJ, Dileo MV, Bishop JV, Zhou FH, et al. Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int. 2012;81:363–9.
Mikhova KM, Don CW, Laflamme M, Kellum JA, Mulligan MS, Verrier ED, et al. Effect of cytokine hemoadsorption on brain death-induced ventricular dysfunction in a porcine model. J Thorac Cardiovasc Surgery. 2013;145:215–23 (discussion 23-4).
Hetz H, Berger R, Recknagel P, Steltzer H. Septic shock secondary to beta-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy. Int J Artif Organs. 2014;37:422–6.
Mitzner SR, Gloger M, Henschel J, Koball S. Improvement of hemodynamic and inflammatory parameters by combined hemoadsorption and hemodiafiltration in septic shock: a case report. Blood Purif. 2013;35:314–5.
Hinz B, Jauch O, Noky T, Friesecke S, Abel P, Kaiser R. CytoSorb, a novel therapeutic approach for patients with septic shock: a case report. Int J Artif Organs. 2015;38:461–4.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165–228.
Reiter K, Bordoni V, Dall’Olio G, Ricatti MG, Soli M, Ruperti S, et al. In vitro removal of therapeutic drugs with a novel adsorbent system. Blood Purif. 2002;20:380–8.
Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301:2445–52.
Bayer O, Reinhart K, Kohl M, Kabisch B, Marshall J, Sakr Y, et al. Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance, and patient outcomes in patients with severe sepsis: a prospective sequential analysis. Crit Care Med. 2012;40:2543–51.
Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26:1793–800.
Haas SA, Lange T, Saugel B, Petzoldt M, Fuhrmann V, Metschke M, et al. Severe hyperlactatemia, lactate clearance and mortality in unselected critically ill patients. Intensive Care Med. 2016;42:202–10.
Nguyen HB, Loomba M, Yang JJ, Jacobsen G, Shah K, Otero RM, et al. Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock. J Inflamm. 2010;7:6.
Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med. 2004;32:1637–42.
Marty P, Roquilly A, Vallee F, Luzi A, Ferre F, Fourcade O, et al. Lactate clearance for death prediction in severe sepsis or septic shock patients during the first 24 hours in Intensive Care Unit: an observational study. Ann Intensive Care. 2013;3:3.
Turnbull IR, Javadi P, Buchman TG, Hotchkiss RS, Karl IE, Coopersmith CM. Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock. 2004;21:121–5.
Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A, Asfar P, et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med. 2010;36:2019–29.
Shiga H, Hirasawa H, Nishida O, Oda S, Nakamura M, Mashiko K, et al. Continuous hemodiafiltration with a cytokine-adsorbing hemofilter in patients with septic shock: a preliminary report. Blood Purif. 2014;38:211–8.
Peng Z, Singbartl K, Simon P, Rimmele T, Bishop J, Clermont G, et al. Blood purification in sepsis: a new paradigm. Contrib Nephrol. 2010;165:322–8.
Peng ZY, Bishop JV, Wen XY, Elder MM, Zhou F, Chuasuwan A, et al. Modulation of chemokine gradients by apheresis redirects leukocyte trafficking to different compartments during sepsis, studies in a rat model. Crit Care. 2014;18:R141.
Bello G, Di Muzio F, Maviglia R, Antonelli M. New membranes for extracorporeal blood purification in septic conditions. Minerva Anestesiol. 2012;78:1265–81.
Venkataraman R, Subramanian S, Kellum JA. Clinical review: extracorporeal blood purification in severe sepsis. Crit Care. 2003;7:139–45.
Zhou F, Peng Z, Murugan R, Kellum JA. Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med. 2013;41:2209–20.
Antonelli M, Cutuli SL, Ronco C. Polymyxin B hemoperfusion in septic shock: just look at the evidence! Intensive Care Med. 2015;41:1731–2.
Trager K, Fritzler D, Fischer G, Schroder J, Skrabal C, Liebold A, et al. Treatment of post-cardiopulmonary bypass SIRS by hemoadsorption: a case series. Int J Artif Organs. 2016;39:141–6.
Cornejo R, Downey P, Castro R, Romero C, Regueira T, Vega J, et al. High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med. 2006;32:713–22.
Vieillard-Baron A, Caille V, Charron C, Belliard G, Aegerter P, Page B, et al. Reversal of refractory septic shock with drotrecogin alpha (activated). Intensive Care Med. 2009;35:1204–9.
Donati A, Domizi R, Damiani E, Adrario E, Pelaia P, Ince C. From macrohemodynamic to the microcirculation. Crit Care Res Pract. 2013;2013:892710.
We are indebted to the nursing staff of our intensive care unit and the staff of the dialysis department for their excellent work. We thank Mr. Sebastian Maletzki for his help with the data collection and data presentation.
Ethics approval and consent to participate
This study was approved by the institutional ethics committee of the Ernst Moritz Arndt University Greifswald (No. BB 048/13). Written informed consent was obtained from patients or their legal representatives.
Conflict of interest
CytoSorbents Europe supplied the hemadsorption cartridges used in this study free of charge. SF has received lecture honoraria, AN has received lecture honoraria and travel reimbursements from CytoSorbents Europe. SSS, SG and SBF declare no conflicts of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Fig. 3: Interleukin 6 levels before and during treatment with CytoSorb®. Values are shown as mean with 95% CIs in logarithmic scale. Mean and 95%CI values of log-transformed outcomes were accordingly back-transformed to the original scale. Difference vs. “d0” (before CytoSorb® start): ** p < 0.01, *** p < 0.001 (DOC 42 kb)
About this article
Cite this article
Friesecke, S., Stecher, SS., Gross, S. et al. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs 20, 252–259 (2017). https://doi.org/10.1007/s10047-017-0967-4
- Septic shock therapy
- Refractory septic shock
- Interleukin 6
- Blood purification